NOVAVAX INC Income Taxes Paid
NOVAVAX INC (NVAX) reported Income Taxes Paid of $190.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-28.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:IncomeTaxesPaid · last filed 2024-02-28
- NOVAVAX INC income taxes paid for the quarter ending 2023-12-31 was $62.00K, a 54.74% decline year-over-year.
- NOVAVAX INC income taxes paid for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- NOVAVAX INC income taxes paid for the quarter ending 2023-06-30 was $128.00K, a 94.50% decline year-over-year.
- NOVAVAX INC income taxes paid for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- NOVAVAX INC income taxes paid for fiscal 2023 was $190.00K, a 98.94% decline from fiscal 2022.
- NOVAVAX INC income taxes paid for fiscal 2022 was $17.98M, a 42.63% increase from fiscal 2021.
- NOVAVAX INC income taxes paid for fiscal 2021 was $12.61M.
- NOVAVAX INC income taxes paid for fiscal 2020 was $0.00.
| Period end | Income Taxes Paid 3 month | Income Taxes Paid 6 month | Income Taxes Paid 9 month | Income Taxes Paid 12 month |
|---|---|---|---|---|
| 2023-12-31 | $62.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $62.00K derived: sum of 2 quarters · filed 2024-02-28 | $190.00K derived: sum of 3 quarters · filed 2024-02-28 | $190.00K 10-K · filed 2024-02-28 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $128.00K derived: sum of 2 quarters · filed 2023-11-09 | $128.00K 10-Q · filed 2023-11-09 | $265.00K derived: sum of 4 quarters · filed 2024-02-28 |
| 2023-06-30 | $128.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $128.00K 10-Q · filed 2023-08-08 | $265.00K derived: sum of 3 quarters · filed 2024-02-28 | $330.00K derived: sum of 4 quarters · filed 2024-02-28 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 | $137.00K derived: sum of 2 quarters · filed 2024-02-28 | $202.00K derived: sum of 3 quarters · filed 2024-02-28 | $2.53M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-12-31 | $137.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $202.00K derived: sum of 2 quarters · filed 2024-02-28 | $2.53M derived: sum of 3 quarters · filed 2024-02-28 | $17.98M 10-K · filed 2024-02-28 |
| 2022-09-30 | $65.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $2.39M derived: sum of 2 quarters · filed 2023-11-09 | $17.84M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $2.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $17.78M 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $15.45M 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $12.61M 10-K · filed 2024-02-28 | |||
| 2021-03-31 | $3.02M 10-Q · filed 2021-05-10 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-28 | |||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |